CRMD Stock Overview
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
CorMedix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.12 |
| 52 Week High | US$8.03 |
| 52 Week Low | US$2.65 |
| Beta | 2.35 |
| 1 Month Change | 7.15% |
| 3 Month Change | 29.97% |
| 1 Year Change | 7.01% |
| 3 Year Change | -38.42% |
| 5 Year Change | 79.13% |
| Change since IPO | -72.53% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 16
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Mar 01Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Sep 09CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price
Feb 11We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely
Jan 04Shareholder Returns
| CRMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.4% | -0.04% | 3.1% |
| 1Y | 7.0% | 7.9% | -8.5% |
Return vs Industry: CRMD matched the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: CRMD exceeded the US Market which returned -9.4% over the past year.
Price Volatility
| CRMD volatility | |
|---|---|
| CRMD Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CRMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CRMD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 30 | Joe Todisco | https://www.cormedix.com |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. Fundamentals Summary
| CRMD fundamental statistics | |
|---|---|
| Market Cap | US$169.99m |
| Earnings (TTM) | -US$29.28m |
| Revenue (TTM) | US$92.10k |
1,846x
P/S Ratio-5.8x
P/E RatioIs CRMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRMD income statement (TTM) | |
|---|---|
| Revenue | US$92.10k |
| Cost of Revenue | US$51.34k |
| Gross Profit | US$40.77k |
| Other Expenses | US$29.32m |
| Earnings | -US$29.28m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 44.26% |
| Net Profit Margin | -31,794.56% |
| Debt/Equity Ratio | 0% |
How did CRMD perform over the long term?
See historical performance and comparison